Myotonic Dystrophy Type 1 research hub

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

This study is testing a new medicine, DYNE-101, for people with Myotonic Dystrophy Type 1. It compares the new medicine to a dummy treatment over 48 weeks to see if it's safe and helps improve daily activities.